Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

Todd Neale

March 08, 2024

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Daily News

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Shelley Wood

May 09, 2023

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Shelley Wood

June 01, 2020

News Daily News

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

Shelley Wood

May 06, 2020

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

Advertisement

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Little Pre- and Postmarket Testing for Most Recalled CV Devices

FDA Grants MACE Reduction Indication for Semaglutide

FDA Grants Tirzepatide a New Indication for Obesity Management

FDA Approves Paradise Renal Denervation System: What Comes Next?

FDA Approves Colchicine for Decreasing CV Events

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

FDA Approves Empagliflozin for Treatment of HFpEF

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

FDA Approves Dapagliflozin for CKD Patients

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content